Qualitative and quantitative effects of aggressive lipid-lowering therapy on atherosclerosis: Evaluation of vulnerable plaque by 64-slice MD-CT - Qualitative and quantitative effects of aggressive lipid-lowering therapy on atherosclerosis: Evaluation of vulnerable plaque by 64-slice MD-CT

Sakurabashi Watanabe Hospital0 个研究点目标入组 50 人开始时间: 2008年12月26日最近更新: 2023年10月17日

试验速览

暂无简介。

•1) Patients who have received statins within one month before the study entry 2) Patient who doesn't obtain accurate CT value (ex: plaque contains thrombus.) 3) Patients who need to receive other lipid-lowering drugs apart from the test drug 4) Patients with the fasting TG level of more than 400 mg/dL 5) Patients with uncontrolled hypertension (SBP >= 160mmHg or DBP >= 100mmHg) or patients with diabetes (HbA1c >= 8.0%) 6) Patients with familial hypercholesterolemia 7) Patients with secondary hyperlipidemia due to thyroid dysfunction, Cushing's syndrome, nephrotic syndrome, systemic lupus erythematosus, etc. 8) Patients with atrial fibrillation 9) Patients on treatment with cyclosporine 10) Patients currently receiving hemodialysis 11) Patients with a history of serious adverse effects or allergy to HMG-CoA reductase inhibitors 12) Patients with malignant tumor or doubtful malignant tumor, or patients with history of malignant tumor 13) Patients with active liver disease or hepatic dysfunction (ALT, AST, ALP levels more than 2.5 times the upper limit of normal, or a total bilirubin of more than 3.0 mg/dL) 14) Patients with the serum creatinine of more than 1.8 mg/dL 15) Patients with the serum CK level at least 3 times the upper limit of normal 16) Patients who can not take -blockers 17) Patients with confirmed pregnancy, possible pregnancy 18) Patients who underwent coronary PCI 19) Patients who are ineligible for any other reason in the opinion of the investigator

发起方

Sakurabashi Watanabe Hospital